WASHINGTON – The Biden administration is preparing to reveal a pharmaceutical pricing agreement with Regeneron Pharmaceuticals this Thursday, according to an individual with knowledge of the negotiations.
Among 17 major pharmaceutical corporations that received correspondence from former President Donald Trump last July regarding drug pricing negotiations, Regeneron remained the only company that had not yet finalized such an arrangement.
When contacted by Reuters for a statement, Regeneron did not provide an immediate response.
The pharmaceutical company’s stock price climbed more than 2% during Thursday morning market activity.
